Abstract
Unmet clinical needs for the management of insulinoma include a low proportion of patients having surgical treatment, postoperative diabetes mellitus, and residual hypoglycemia. Glucagon-like peptide-1 (GLP-1) receptor-targeted imaging such as that using [(18) F]FB(ePEG12)12-exendin-4 positron emission tomography (PET) is promising and may fill unmet clinical needs.